Low ‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia
In conclusion, preliminary results indicated that low-dose venetoclax combined with azacitidine is effective and safe for the treatment of older and frail patients with newly diagnosed AML, providing a new treatment option for these patients.PMID:38586209 | PMC:PMC10996028 | DOI:10.3892/ol.2024.14362 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Chunmeng Rong Fang Yang Yalu Chen Ming Wang Cheng Ai Yuqing Luo Panpan Gao Yiqin Weng Xiaguang Huang Meier Gu Weiping Huang Yongming Xia Source Type: research
Drug resistance ‑related gene targets and molecular mechanisms in the A2780/Taxol‑resistant epithelial ovarian cancer cell line
Oncol Lett. 2024 Mar 26;27(5):232. doi: 10.3892/ol.2024.14365. eCollection 2024 May.ABSTRACTEpithelial ovarian cancer (EOC) is a fatal gynecological malignant tumor with a low 5-year survival rate. The use of the first-line chemotherapeutic drug, paclitaxel, for the treatment of EOC is associated with resistance, often leading to treatment failure. The present study investigated the gene targets in an A2780 paclitaxel-resistant EOC cell line (A2780/Taxol), and the potential underlying mechanisms using transcriptome sequencing technology and bioinformatics analysis. The transcriptome of the A2780/Taxol cell line was sequenc...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Ruihui Yang Huainian Zhang Zexin Chen Tao Zhang Peng Wei Huaguo Liang Yaoyao He Changtao Zheng Xicheng Wang Yongli Zhang Source Type: research
MicroRNA ‑373‑3p inhibits the proliferation and invasion of non‑small‑cell lung cancer cells by targeting the GAB2/PI3K/AKT pathway
Oncol Lett. 2024 Mar 22;27(5):221. doi: 10.3892/ol.2024.14353. eCollection 2024 May.ABSTRACTMicroRNAs (miRNAs) were previously demonstrated to be involved in the pathogenesis of non-small-cell lung cancer (NSCLC); however, the roles of certain miRNAs in NSCLC remain to be elucidated. The present study aimed to investigate the functions of screened miRNAs in NSCLC and the potential mechanisms. First, expression profiles of miRNAs were downloaded from the Gene Expression Omnibus (dataset no. GSE29248) and the differentially expressed miRNAs were analyzed by bioinformatics methods. Reverse transcription-quantitative PCR was u...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Xunxia Zhu Xiaoyu Chen Xuelin Zhang Liting Zhao Xiaoyong Shen Source Type: research
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK ‑positive NSCLC patients with CNS metastases: A retrospective study
Oncol Lett. 2024 Mar 22;27(5):224. doi: 10.3892/ol.2024.14357. eCollection 2024 May.ABSTRACTAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have transformed the treatment paradigm for patients with ALK-positive non-small cell lung cancer (NSCLC). Yet the differential efficacy between alectinib and crizotinib in treating patients with NSCLC and central nervous system (CNS) metastases has been insufficiently studied. A retrospective analysis was conducted of clinical outcomes of patients with ALK-positive NSCLC and CNS metastases treated at the Shandong Cancer Centre. Based on their initial ALK-TKI treatme...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Qing Liu Ying Fu Jun Guo Chunqiu Fu Ning Tang Chufeng Zhang Xiao Han Zhehai Wang Source Type: research
Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: A case report
Oncol Lett. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. eCollection 2024 May.ABSTRACTGlioblastoma (GBM) is the most common primary malignant brain tumour in adults. The standard of care consists of surgical resection and concurrent chemoradiation, followed by adjuvant temozolomide chemotherapy. This protocol is associated with a median survival of 12-15 months, and <5% of patients survive >3 years. Ketogenic metabolic therapy (KMT) targets cancer cell metabolism by restricting glucose availability and evoking differential stress resistance and sensitization, which may augment the standard treatments and lead t...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Matthew C L Phillips Ziad Thotathil Prashanth Hari Dass Fouzia Ziad Ben G Moon Source Type: research
Diagnostic value of HPV E6/E7 mRNA in screening for cervical intraepithelial neoplasia grade 2 or worse: A systematic review and meta ‑analysis
Oncol Lett. 2024 Mar 26;27(5):231. doi: 10.3892/ol.2024.14364. eCollection 2024 May.ABSTRACTHistology is considered the gold standard for diagnosing the pathological progress of cervical cancer development, while cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) is the cutoff for intervention in clinical practice. The diagnostic value of human papillomavirus (HPV) E6/E7 mRNA in screening for CIN2+ has not been systematically summarized. A meta-analysis was conducted as part of the present study conducted to explore the diagnostic value of HPV E6/E7 mRNA in screening for CIN2+, aiming to provide a new marker fo...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Fengsheng Xu Tianfu Ran Qiangang Wei Rirun Pan Shangzhong Chen Jing Luo Source Type: research
Molecular mechanism of formation and destruction of a pseudo ‑capsule in clear cell renal cell carcinoma
In conclusion, the present study provides insights into the formation and destruction of a PC, and the results may aid the treatment and management of patients with ccRCC.PMID:38586200 | PMC:PMC10996032 | DOI:10.3892/ol.2024.14358 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Takuto Shimizu Makito Miyake Kota Iida Sayuri Onishi Tomomi Fujii Yusuke Iemura Kazuki Ichikawa Chihiro Omori Fumisato Maesaka Mitsuru Tomizawa Tatsuki Miyamoto Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
[Retracted] Predictors of efficacy of anamorelin in patients with non ‑small cell lung cancer and cachexia: A retrospective study
Oncol Lett. 2024 Mar 26;27(5):229. doi: 10.3892/ol.2024.14360. eCollection 2024 May.ABSTRACT[This retracts the article DOI: 10.3892/ol.2023.14154.].PMID:38586201 | PMC:PMC10996008 | DOI:10.3892/ol.2024.14360 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Yoshiko Ishioka Hisashi Tanaka Tomonori Makiguchi Syunsuke Fujishima Yasuhito Nunomura Hiroaki Sakamoto Toshihiro Shiratori Kageaki Taima Sadatomo Tasaka Source Type: research
Internal mammary node abnormality in imaging studies and treatment outcomes in patients with breast cancer
In conclusion, the impact of Mild-IMN on clinical outcomes was small. Although irradiation for cMet-IMN is important, the impact of the cMet-IMN boost with 10 Gy in 5 fractions on clinical outcomes may also be limited.PMID:38586202 | PMC:PMC10995659 | DOI:10.3892/ol.2024.14352 (Source: Oncology Letters)
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Kenji Makita Yasushi Hamamoto Hiromitsu Kanzaki Kei Nagasaki Kenjiro Aogi Source Type: research
Intrapleural perfusion hyperthermia improves the efficiency of anti ‑PD1 antibody‑based therapy for lung adenocarcinoma: A case report
Oncol Lett. 2024 Mar 21;27(5):217. doi: 10.3892/ol.2024.14351. eCollection 2024 May.ABSTRACTChemotherapy based on intrapleural perfusion hyperthermia (IPH) can markedly improve the sensitivity of lung adenocarcinoma cells to anti-programmed cell death receptor 1 (PD1) antibody adjuvant chemotherapy and enhance the clinical response of a patient. In the present study, a unique case of a patient who failed to respond to immunotherapy combined with chemotherapy but achieved prolonged stable disease after treatment with IPH and subsequent sintilimab-based treatment, is reported. A 50-year-old Chinese female patient was admitte...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Xiaolei Wang Jin Song Ling Hu Guanying Ren Nan Geng Zizheng Song Source Type: research
Simultaneous blastic plasmacytoid dendritic cell neoplasm and myelofibrosis: A case report
Oncol Lett. 2024 Mar 22;27(5):220. doi: 10.3892/ol.2024.14354. eCollection 2024 May.ABSTRACTBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare and aggressive tumor with an unknown pathogenesis. Myelofibrosis (MF) is a type of myeloproliferative neoplasm. MF can be secondary to several hematological malignancies, including chronic myeloid leukemia, myelodysplastic syndrome and hairy cell leukemia. In the present report, a rare case of BPDCN secondary to MF is described. A 70-year-old male patient developed a large purplish-red rash with recurrent symptoms. BPDCN was confirmed by immunohistochemistry o...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Fuyi Luo Bingjie Li Jing Li Yan Li Source Type: research
LncRNA HOXA ‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis
In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these ...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Tijun Xiao An Yan Lifang Tan Hongwei Zhu Wenzhe Gao Source Type: research
hsa ‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel
Oncol Lett. 2024 Mar 21;27(5):219. doi: 10.3892/ol.2024.14350. eCollection 2024 May.ABSTRACTLung cancer is the leading cause of cancer-related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first-line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse events, particularly hematological reactions. Studies on new biomarkers related to these adverse events, such as circulating microRNAs (miRNAs/miRs), are...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Pedro Eduardo Nascimento Silva Vasconcelos Cec ília Souto Seguin Arist óteles de Souza Barbeiro Lair Zambon Helen Naemi Honma Maur ício Wesley Perroud Murilo Vieira Geraldo Eder de Carvalho Pincinato Patricia Moriel Source Type: research
Skipped sentinel lymph node basin in a patient with forearm cutaneous melanoma: A case report
Oncol Lett. 2024 Mar 26;27(5):233. doi: 10.3892/ol.2024.14366. eCollection 2024 May.ABSTRACTSentinel lymph node biopsy is an important tool in the management of malignant melanoma, particularly in predicting micrometastasis to regional lymph nodes. Cases of secondary drainage to lymph nodes outside of conventional nodal basins and overall unusual lymph node localization have been reported. The present study reports a unique case of a 'skipped sentinel lymph node basin' pattern in a patient with a right forearm malignant melanoma. Lymphatic mapping using cutaneous lymphoscintigraphy revealed localization at the right suprac...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Olivier F Noel James Clune Source Type: research
FOXP2 inhibits the aggressiveness of lung cancer cells by blocking TGF β signaling
Oncol Lett. 2024 Mar 26;27(5):227. doi: 10.3892/ol.2024.14361. eCollection 2024 May.ABSTRACTLung cancer is associated with high morbidity and mortality rates. Forkhead box P2 (FOXP2) functions as an antitumor gene in various cancers. However, its role in lung cancer remains to be elucidated. The present study explored the potential role of FOXP2 in lung cancer. mRNA levels and protein expression were determined using RT-qPCR and western blotting, respectively. Functional analysis was performed using the CCK-8, Transwell and TUNEL assays. FOXP2 expression was downregulated in lung cancer. Notably, FOXP2 suppressed the proli...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Wenya Su Song Hu Lin Zhou Hui Bi Zhiying Li Source Type: research
